{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:53:54Z","timestamp":1794106434291,"version":"4.8.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009991","name":"Jilin Province Department of Finance","doi-asserted-by":"publisher","award":["2023SCZ09"],"award-info":[{"award-number":["2023SCZ09"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011789","name":"Jilin Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["20240601013RC"],"award-info":[{"award-number":["20240601013RC"]}],"id":[{"id":"10.13039\/501100011789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Jilin Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS118"],"award-info":[{"award-number":["YDZJ202201ZYTS118"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biopha.2024.117204","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T08:51:55Z","timestamp":1721983915000},"page":"117204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Molecular characteristics and systemic treatment options of liposarcoma: A systematic review"],"prefix":"10.1016","volume":"178","author":[{"given":"Xuan-Peng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Peng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan-Biao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Qi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020294","article-title":"Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing","volume":"6","author":"Ducimeti\u00e8re","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","article-title":"Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"von Mehren","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"19","key":"10.1016\/j.biopha.2024.117204_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194578","article-title":"The Immune Contexture of Liposarcoma and Its Clinical Implications","volume":"14","author":"Resag","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.117204_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102668","article-title":"MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action","volume":"122","author":"Somaiah","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2024.117204_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cncr.29931","article-title":"External validation of a multi-institutional retroperitoneal sarcoma nomogram","volume":"122","author":"Raut","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jss.2011.07.024","article-title":"Predicting survival for well-differentiated liposarcoma: the importance of tumor location","volume":"175","author":"Smith","year":"2012","journal-title":"J. Surg. Res"},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119571","article-title":"Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy","volume":"24","author":"Zhou","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20835","article-title":"Evaluation of well-differentiated\/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization","volume":"50","author":"Tap","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.biopha.2024.117204_bib9","first-page":"247","article-title":"TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer","volume":"157","author":"Olivier","year":"2004","journal-title":"IARC Sci. Publ."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the Light: The Growing Complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2006.01.020","article-title":"p53 ubiquitination: Mdm2 and beyond","volume":"21","author":"Brooks","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.117204_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/483154","article-title":"Liposarcoma: molecular genetics and therapeutics","volume":"2011","author":"Conyers","year":"2011","journal-title":"Sarcoma"},{"issue":"6","key":"10.1016\/j.biopha.2024.117204_bib13","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.biopha.2024.117204_bib14","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-07-0584","article-title":"Gene expression profiling of liposarcoma identifies distinct biological types\/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma","volume":"67","author":"Singer","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.semdp.2019.02.006","article-title":"Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review","volume":"36","author":"Thway","year":"2019","journal-title":"Semin Diagn. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.sla.0000086542.11899.38","article-title":"Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma","volume":"238","author":"Singer","year":"2003","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00000478-199703000-00002","article-title":"Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation","volume":"21","author":"Henricks","year":"1997","journal-title":"Am. J. Surg. Pathol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(23)00462-X","article-title":"A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis","volume":"24","author":"Arthur","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117204_bib19","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/01.pas.0000170343.09562.39","article-title":"MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data","volume":"29","author":"Binh","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10735-024-10195-4","article-title":"An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies","volume":"55","author":"M","year":"2024","journal-title":"J. Mol. Histol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat. Genet"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.onc.1201952","article-title":"Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts","volume":"17","author":"Fedele","year":"1998","journal-title":"Oncogene"},{"issue":"40","key":"10.1016\/j.biopha.2024.117204_bib23","doi-asserted-by":"crossref","first-page":"42429","DOI":"10.18632\/oncotarget.6464","article-title":"Genomic landscape of liposarcoma","volume":"6","author":"Kanojia","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biopha.2024.117204_bib24","first-page":"495","article-title":"Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors","volume":"2","author":"Meltzer","year":"1991","journal-title":"Cell Growth Differ."},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib25","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/MCB.02185-05","article-title":"GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation","volume":"26","author":"Park","year":"2006","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0165-4608(02)00614-3","article-title":"A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas","volume":"139","author":"Chibon","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib27","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/modpathol.2009.119","article-title":"Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma","volume":"22","author":"Horvai","year":"2009","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/2159-8290.CD-11-0181","article-title":"Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas","volume":"1","author":"Taylor","year":"2011","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib29","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-10-3588","article-title":"Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis","volume":"71","author":"Gobble","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccr.2007.02.007","article-title":"JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas","volume":"11","author":"Mariani","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/gcc.20012","article-title":"ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications","volume":"40","author":"Chibon","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11864-023-01057-4","article-title":"Myxoid Liposarcomas: Systemic Treatment Options","volume":"24","author":"Nassif","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2024.117204_bib33","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1016\/j.ejca.2005.07.023","article-title":"Differential sensitivity of liposarcoma subtypes to chemotherapy","volume":"41","author":"Jones","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2004.03.009","article-title":"Radiation response: an additional unique signature of myxoid liposarcoma","volume":"60","author":"Pitson","year":"2004","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2017.74.9598","article-title":"Clinical and Molecular Spectrum of Liposarcoma","volume":"36","author":"Lee","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2024.117204_bib36","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1002\/cam4.3039","article-title":"Clinical outcomes of patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma treated at major cancer centers in the United States","volume":"9","author":"Pollack","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11864-023-01064-5","article-title":"Myxoid Liposarcoma: How to Stage and Follow","volume":"24","author":"Ho","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.biopha.2024.117204_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/538085","article-title":"Prognostic factors and metastatic patterns in primary myxoid\/round-cell liposarcoma","volume":"2011","author":"Haniball","year":"2011","journal-title":"Sarcoma"},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00000478-199602000-00005","article-title":"Myxoid\/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma","volume":"20","author":"Smith","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"issue":"6430","key":"10.1016\/j.biopha.2024.117204_bib40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/363640a0","article-title":"Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma","volume":"363","author":"Crozat","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/MCB.00884-09","article-title":"TLS inhibits RNA polymerase III transcription","volume":"30","author":"Tan","year":"2010","journal-title":"Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117204_bib42","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.molcel.2022.03.019","article-title":"The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma","volume":"82","author":"Zullow","year":"2022","journal-title":"Mol. Cell"},{"issue":"14","key":"10.1016\/j.biopha.2024.117204_bib43","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-09-2912","article-title":"Functional mapping of receptor tyrosine kinases in myxoid liposarcoma","volume":"16","author":"Negri","year":"2010","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib44","first-page":"274","article-title":"Pleomorphic liposarcoma","volume":"18","author":"Oliveira","year":"2001","journal-title":"Semin Diagn. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib45","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/modpathol.3880280","article-title":"Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases","volume":"14","author":"Downes","year":"2001","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117204_bib46","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/00000478-200205000-00006","article-title":"Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group","volume":"26","author":"Gebhard","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"issue":"10","key":"10.1016\/j.biopha.2024.117204_bib47","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/01.pas.0000135524.73447.4a","article-title":"Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases","volume":"28","author":"Hornick","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117204_bib48","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/PAS.0b013e3181963c9c","article-title":"Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age","volume":"33","author":"Alaggio","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib49","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/annonc\/mds219","article-title":"Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib50","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.3928\/01477447-20220719-05","article-title":"Pleomorphic Liposarcoma Revisited","volume":"46","author":"Hadjimichael","year":"2023","journal-title":"Orthopedics"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib51","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.soc.2016.05.002","article-title":"Imaging in Soft Tissue Sarcomas: Current Updates","volume":"25","author":"Jagannathan","year":"2016","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.semdp.2019.02.007","article-title":"Pleomorphic liposarcoma: Updates and current differential diagnosis","volume":"36","author":"Anderson","year":"2019","journal-title":"Semin Diagn. Pathol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117204_bib53","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/PAS.0b013e3182562bc1","article-title":"Liposarcomas of the mediastinum and thorax: a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features","volume":"36","author":"Boland","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.path.2023.06.005","article-title":"Myxoid Pleomorphic Liposarcoma","volume":"17","author":"Dermawan","year":"2024","journal-title":"Surg. Pathol. Clin."},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib55","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/s41379-022-01107-6","article-title":"Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study","volume":"35","author":"Dermawan","year":"2022","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib56","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/CCO.0000000000000954","article-title":"Next questions in the management of retroperitoneal sarcoma","volume":"35","author":"Drohan","year":"2023","journal-title":"Curr. Opin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib57","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdr323","article-title":"Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas","volume":"23","author":"Gronchi","year":"2012","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib58","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117204_bib59","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2214\/AJR.07.3746","article-title":"Recurrence of retroperitoneal liposarcoma: imaging findings and growth rates at follow-up CT. AJR","volume":"191","author":"Kim","year":"2008","journal-title":"Am. J. Roentgenol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117204_bib60","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1245\/s10434-022-12977-0","article-title":"Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma","volume":"30","author":"Eckardt","year":"2023","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1996.14.3.859","article-title":"Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma","volume":"14","author":"Pisters","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib62","first-page":"305","article-title":"The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg","volume":"196","author":"Rosenberg","year":"1982"},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib63","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.1998.16.1.197","article-title":"Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity","volume":"16","author":"Yang","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.117204_bib64","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ejso.2022.08.029","article-title":"The role of standard and novel radiotherapy approaches in management of retroperitoneal sarcomas","volume":"49","author":"Wiltink","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib65","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.31927","article-title":"Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group","volume":"125","author":"Haas","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib66","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1245\/s10434-021-11156-x","article-title":"Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma","volume":"29","author":"Ng","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117204_bib67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jso.21474","article-title":"Radiotherapy and extent of surgical resection in retroperitoneal soft-tissue sarcoma: multi-institutional analysis of 261 patients","volume":"101","author":"Sampath","year":"2010","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib68","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.5865","article-title":"Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial","volume":"7","author":"Lansu","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.1993.11.1.15","article-title":"Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","volume":"11","author":"Steward","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib70","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/0284186X.2017.1315173","article-title":"Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study","volume":"56","author":"Young","year":"2017","journal-title":"Acta Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib71","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2024.117204_bib72","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib73","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1002\/cam4.5298","article-title":"Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma","volume":"12","author":"Thirasastr","year":"2023","journal-title":"Cancer Med"},{"issue":"18","key":"10.1016\/j.biopha.2024.117204_bib74","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib75","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.suronc.2017.01.008","article-title":"Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: Evidence from a nationwide clinical oncology database and review of the literature","volume":"26","author":"Datta","year":"2017","journal-title":"Surg. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib76","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2024.117204_bib77","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24614","article-title":"Trabectedin: A drug from the sea that strikes tumor-associated macrophages","volume":"2","author":"Allavena","year":"2013","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib79","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117204_bib80","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.biopha.2024.117204_bib81","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib82","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.biopha.2024.117204_bib83","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.32117","article-title":"Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib84","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117204_bib85","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jamaoncol.2023.0056","article-title":"Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial","volume":"9","author":"Sanfilippo","year":"2023","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib86","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib87","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","article-title":"Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase","volume":"7","author":"Okouneva","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib88","first-page":"1013","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"issue":"10028","key":"10.1016\/j.biopha.2024.117204_bib89","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"30","key":"10.1016\/j.biopha.2024.117204_bib90","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","article-title":"Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine","volume":"35","author":"Demetri","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10043","key":"10.1016\/j.biopha.2024.117204_bib91","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib92","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.25843","article-title":"Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma","volume":"129","author":"Mahmood","year":"2011","journal-title":"Int J. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2024.117204_bib93","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117204_bib94","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cncr.26334","article-title":"Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas","volume":"118","author":"von Mehren","year":"2012","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.biopha.2024.117204_bib95","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9829","key":"10.1016\/j.biopha.2024.117204_bib96","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib97","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaoncol.2020.6564","article-title":"Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and\/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial","volume":"7","author":"Schmoll","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib98","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ijc.22643","article-title":"Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A","volume":"121","author":"M\u00fcller","year":"2007","journal-title":"Int J. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib99","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.biopha.2024.117204_bib100","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1038\/sj.onc.1210136","article-title":"Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1","volume":"26","author":"Ambrosini","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2024.117204_bib101","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/OTT.S440979","article-title":"Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series","volume":"17","author":"Yamamoto","year":"2024","journal-title":"Onco Targets Ther."},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib102","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.biopha.2024.117204_bib103","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fon-2022-1291","article-title":"Brightline-1: phase II\/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS","volume":"19","author":"Sch\u00f6ffski","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.biopha.2024.117204_bib104","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2017.02.005","article-title":"A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours","volume":"76","author":"de Jonge","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2024.117204_bib105","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2016.70.7117","article-title":"Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors","volume":"35","author":"Wagner","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117204_bib106","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117204_bib107","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-11-3203","article-title":"The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial","volume":"18","author":"Luke","year":"2012","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.biopha.2024.117204_bib108","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/bjc.2011.177","article-title":"Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2\/1)","volume":"104","author":"Schwartz","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib109","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol."},{"issue":"23","key":"10.1016\/j.biopha.2024.117204_bib110","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A Phase I Study of the Cyclin-Dependent Kinase 4\/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas","volume":"22","author":"Infante","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.biopha.2024.117204_bib111","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-21-1291","article-title":"Co-Targeting of MDM2 and CDK4\/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study","volume":"28","author":"Abdul Razak","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib112","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.CCR-23-2378","article-title":"Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma","volume":"30","author":"Gleason","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib113","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1073\/pnas.94.1.237","article-title":"Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor","volume":"94","author":"Tontonoz","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib114","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1073\/pnas.96.7.3951","article-title":"Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma","volume":"96","author":"Demetri","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"21","key":"10.1016\/j.biopha.2024.117204_bib115","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1002\/cncr.27526","article-title":"A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies","volume":"118","author":"Pishvaian","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib116","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/sj.bjc.6601306","article-title":"A phase II trial with rosiglitazone in liposarcoma patients","volume":"89","author":"Debrock","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2024.117204_bib117","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cncr.30926","article-title":"Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"123","author":"Samuels","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib118","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41416-021-01448-0","article-title":"Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas","volume":"125","author":"Schulte","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2024.117204_bib119","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamaoncol.2022.3218","article-title":"Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG)","volume":"8","author":"Sanfilippo","year":"2022","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib120","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib121","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1847846","article-title":"A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1","volume":"9","author":"Somaiah","year":"2020","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.biopha.2024.117204_bib122","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1158\/1078-0432.CCR-22-0240","article-title":"A Phase 1\/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma","volume":"28","author":"Wagner","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.biopha.2024.117204_bib123","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.20.03452","article-title":"Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1","volume":"40","author":"Chawla","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2024.117204_bib124","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"40","author":"Gounder","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2024.117204_bib125","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1002\/cncr.27446","article-title":"NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid\/round cell liposarcoma","volume":"118","author":"Pollack","year":"2012","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2024.117204_bib126","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2024.117204_bib127","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib128","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.18632\/oncotarget.6547","article-title":"Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma","volume":"7","author":"Patwardhan","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib129","article-title":"Current development of cabazitaxel drug delivery systems","volume":"15","author":"Sun","year":"2023","journal-title":"Wiley Inter. Rev. Nanomed. Nanobiotechnol"},{"issue":"4","key":"10.1016\/j.biopha.2024.117204_bib130","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/CCO.0000000000000955","article-title":"New targeted treatments for advanced sarcomas","volume":"35","author":"Li","year":"2023","journal-title":"Curr. Opin. Oncol."},{"issue":"26","key":"10.1016\/j.biopha.2024.117204_bib131","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2024.117204_bib132","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-10-3216","article-title":"Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6","volume":"17","author":"Guan","year":"2011","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2024.117204_bib133","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijsu.2020.04.033","article-title":"Invited Commentary on:The Results of Pancreatic Operations after the Implementation of Multidisciplinary Team Conference (MDT): A Quality Improvement Study","volume":"78","author":"Hendi","year":"2020","journal-title":"Int J. Surg."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010299","article-title":"Ovarian Cancer in a Northern Italian Province and the Multidisciplinary Team","volume":"15","author":"Mangone","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2024.117204_bib135","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/curroncol29020102","article-title":"The Prognostic Effect of Multidisciplinary Team Intervention in Patients with Advanced Gastric Cancer","volume":"29","author":"Xiang","year":"2022","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.117204_bib136","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/annonc\/mdt407","article-title":"Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study","volume":"25","author":"Mathoulin-P\u00e9lissier","year":"2014","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117204_bib137","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.surg.2024.01.012","article-title":"Clinical and surgical effectiveness of the multi-disciplinary standardized management model in the treatment of retroperitoneal liposarcoma: Evidence-based clinical practice experience from Fudan Zhongshan","volume":"175","author":"Fan","year":"2024","journal-title":"Surgery"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224010886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:28:02Z","timestamp":1777861682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224010886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":137,"alternative-id":["S0753332224010886"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117204","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characteristics and systemic treatment options of liposarcoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117204"}}